Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — specifically a trans-3-hexenoic acid modification of GHRH(1–44). It is among the most extensively studied GHRH analogues, having undergone Phase III clinical trials in the United States, where it was investigated for reduction of visceral adipose tissue (VAT). Its selectivity for abdominal fat depots makes it a highly targeted compound in metabolic research.
What Is Tesamorelin?
Endogenous GHRH is a 44-amino acid hypothalamic peptide that stimulates somatotroph cells in the anterior pituitary to release growth hormone. Native GHRH has a very short half-life — it is rapidly degraded by dipeptidyl peptidase IV (DPP-IV). Tesamorelin's trans-3-hexenoic acid modification at the N-terminus substantially increases its resistance to DPP-IV cleavage, extending its biological activity while preserving full GHRH receptor agonism.
Because Tesamorelin acts upstream at the GHRH receptor rather than injecting exogenous GH directly, it stimulates the pituitary's own GH secretion in pulsatile fashion — preserving the natural feedback architecture of the hypothalamic-pituitary-somatotroph axis. This is a key distinction from direct GH administration.
Visceral Fat: Why It Is a Distinct Research Target
Visceral adipose tissue — the fat stored within the abdominal cavity surrounding internal organs — is metabolically distinct from subcutaneous fat. VAT is highly lipolytically active, releases inflammatory cytokines, and is associated with a range of metabolic and cardiovascular risk markers. It is also notably more resistant to dietary and exercise interventions than subcutaneous fat depots.
Tesamorelin's clinical investigation focused specifically on VAT reduction. The proposed mechanism is GH-driven stimulation of lipolysis in visceral adipocytes, which are particularly sensitive to GH receptor signalling compared to subcutaneous adipocytes. Research subjects showed significant reductions in trunk fat with minimal changes in peripheral (limb) fat, supporting the hypothesis of depot-selective activity.
Research Dosage Protocol
Standard research dosage: 1–2 mg per day via subcutaneous injection
Injection site: Abdomen (subcutaneous), rotating sites
Timing: Evening administration is often used to align with endogenous nocturnal GH pulsatility
Cycle length: 12–26 weeks; research shows effects on VAT are visible from 12 weeks and continue with longer exposure
For dose calculation after reconstitution, use the BAC Water Reconstitution Calculator — enter vial size, BAC water volume, and target dose in mg to get exact IU draw.
GH Pulse Preservation and the Hypothalamic-Pituitary Axis
An important consideration in GHRH analogue research is the maintenance of feedback regulation. Tesamorelin stimulates GH release in pulses rather than flooding the system with continuous GH signal. This preserves somatostatin-mediated feedback, reducing the risk of GH-associated side effects observed with direct GH injection at equivalent GH area-under-curve values.
Researchers interested in GH secretagogue stacking often combine a GHRH analogue with a GHRP or GH secretagogue. Tesamorelin pairs well with CJC-1295 (no-DAC) in some research frameworks — both act on the GHRH receptor, but their half-lives and pulse kinetics differ, allowing researchers to study varying pulse amplitude and frequency profiles.
Storage and Reconstitution
Tesamorelin is supplied as lyophilised powder. Reconstitute with bacteriostatic water using slow wall-drip technique. For a 2mg vial with 1ml BAC water: concentration 2mg/ml = 2000 mcg/ml. A 1mg dose = 0.5ml (50 IU on insulin syringe). Store lyophilised vials at -20°C; reconstituted solution at 2–8°C, use within 3–4 weeks.
Where to Buy Tesamorelin in India
Peptide Central stocks Tesamorelin at 99% purity, HPLC-verified with COA included. Pan-India delivery with COD available. All orders dispatched cold-packed.
Frequently Asked Questions
How does Tesamorelin differ from injecting GH directly?
Tesamorelin stimulates the pituitary to release GH in pulsatile fashion via the GHRH receptor, preserving natural feedback regulation. Direct GH injection bypasses the pituitary and suppresses endogenous GH secretion with prolonged use.
What is the standard Tesamorelin research dosage?
Most research protocols use 1–2 mg per day via subcutaneous injection, typically in the evening to align with the body's natural nocturnal GH release window.
Why does Tesamorelin target visceral fat specifically?
Visceral adipocytes have higher GH receptor density than subcutaneous fat cells, making them more responsive to GH-driven lipolysis. Tesamorelin-stimulated GH pulses preferentially reduce visceral adipose tissue over peripheral fat stores.
Can Tesamorelin be stacked with CJC-1295?
Both are GHRH receptor agonists and would occupy the same receptor — stacking them together is not additive. They are better studied as alternatives to compare pulse kinetics. For GH axis amplification research, a GHRH analogue is typically paired with a ghrelin mimetic such as Ipamorelin instead.